Futura Medical PLC, a consumer healthcare company specializing in sexual health products, has announced Panmure Liberum Limited as its Nominated Adviser and Joint Broker following a recent all-share merger. The company's lead product, Eroxon, is a topically delivered gel formulation designed to treat Erectile Dysfunction (ED). Eroxon is the only over-the-counter topical gel treatment for ED, providing men with the ability to achieve an erection within ten minutes. Futura's focus on addressing significant unmet needs in the ED market is crucial, as ED affects 1 in 5 men globally, with approximately half of all men over 40 experiencing it and 25% of new diagnoses occurring in men under 40. For more information, interested parties can contact the company directly or visit their website.